http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2014145136-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-401 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-501 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-341 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10 |
| filingDate | 2013-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2014145136-A |
| titleOfInvention | LIQUID COMPOSITION |
| abstract | 1. A liquid composition containing propylene glycol and an effective amount of a cardiotonic agent, an angiotensin converting enzyme inhibitor, or a combination of a cardiotonic agent and an angiotensin converting enzyme inhibitor. 2. A liquid formulation containing an effective amount of a cardiotonic agent and propylene glycol. 3. A liquid formulation containing an effective amount of an angiotensin converting enzyme inhibitor and propylene glycol. 4. A liquid composition containing propylene glycol and an effective amount of a combination of a cardiotonic agent and an angiotensin converting enzyme inhibitor. 5. The composition according to any one of paragraphs. 1, 2 and 4, characterized in that the cardiotonic agent is selected from the group consisting of pimobendan, levosimendan, amrinone, enoximon, milrinone, olprinone, springrinone and their pharmaceutically or veterinarily acceptable salts, or a combination thereof. 6. A composition according to claim 5, wherein the cardiotonic agent is pimobendan or a pharmaceutically or veterinarily acceptable salt thereof. The composition according to any one of paragraphs. 1, 3 and 4, characterized in that the angiotensin-converting enzyme inhibitor is selected from the group consisting of enalapril, benazepril, alacepril, captopril, cilazapril, delapril, fosinopril, imidapril, moexipril, spiapril, temocapril, trandaprilopril, peridopril, peridopril, , lisinopril and their pharmaceutically and veterinarily acceptable salts, or combinations thereof. 8. The composition according to claim 7, characterized in that the angiotensin converting enzyme inhibitor is selected from the group consisting of enalapril, benazepril and their pharmaceutically and veterinarily acceptable salts. Composition according to any |
| priorityDate | 2012-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 235.